Synergistic Inhibition of Hepatocellular Carcinoma Growth via Combined mTOR Blockade and Microtubule Disruption
Bulletin of Pioneering Researches of Medical and Clinical Science · 2025 · 5 (1) · 242-259
DOI: 10.51847/3w32mqtxb8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bulletin of Pioneering Researches of Medical and Clinical Science, 2025. Verfasst von Maria Gonzalez und 3 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) poses considerable therapeutic challenges, given that standard chemotherapies offer only restricted benefit. The mammalian target of rapamycin/sirolimus (mTOR) and microtubules represent two major druggable vulnerabilities in HCC. In this work, we demonstrated that concurrent mTOR inhibition with mTOR inhibitors (everolimus and sirolimus) and the microtubule inhibitor vinorelbine yielded outcomes superior to those of single-agent regimens in HCC PDX models. Our dat
Zitieren
APA
Gonzalez, M., Ruiz, J., Torres, L., & Ruiz, E. (2025). Synergistic Inhibition of Hepatocellular Carcinoma Growth via Combined mTOR Blockade and Microtubule Disruption. Bulletin of Pioneering Researches of Medical and Clinical Science, 5(1), 242-259. https://doi.org/10.51847/3w32mqtxb8
Vancouver
Gonzalez M, Ruiz J, Torres L, Ruiz E. Synergistic Inhibition of Hepatocellular Carcinoma Growth via Combined mTOR Blockade and Microtubule Disruption. Bulletin of Pioneering Researches of Medical and Clinical Science. 2025;5(1):242-259. doi:10.51847/3w32mqtxb8
BibTeX
@article{Gonzalez2025,
author = {Gonzalez, Maria and Ruiz, Javier and Torres, Lucia and Ruiz, Elena},
title = {Synergistic Inhibition of Hepatocellular Carcinoma Growth via Combined mTOR Blockade and Microtubule Disruption},
journal = {Bulletin of Pioneering Researches of Medical and Clinical Science},
year = {2025},
volume = {5},
number = {1},
pages = {242--259},
doi = {10.51847/3w32mqtxb8}
}
EUVIMED